Choose Your Country or Region

Belinostat (PXD101)

Name: Belinostat (PXD101)
Brand: Selleck Chemicals
SKU: S1085
Rating: 5 (87 reviews)

Catalog No.S1085 Synonyms: NSC726630, PX-105684

For research use only.

Belinostat (PXD101, NSC726630, PX-105684) is a novel HDAC inhibitor with IC50 of 27 nM in a cell-free assay, with activity demonstrated in cisplatin-resistant tumors. Belinostat (PXD101) induces autophagy.

CAS No. 414864-00-9

Selleck's Belinostat (PXD101) has been cited by 87 publications

Purity & Quality Control

Choose Selective HDAC Inhibitors

Related Compound Libraries

Other HDAC Products

CAY10603^New

CAY10603 (BML-281) is a potent and selective HDAC6 inhibitor with IC50 of 2 pM, >200-fold selectivity over other HDACs.
Domatinostat (4SC-202)^New

Domatinostat (4SC-202) is a selective class I HDAC inhibitor with IC50 of 1.20 μM, 1.12 μM, and 0.57 μM for HDAC1, HDAC2, and HDAC3, respectively. Also displays inhibitory activity against Lysine specific demethylase 1 (LSD1). Phase 1.
Panobinostat (LBH589)

Panobinostat (LBH589, NVP-LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Panobinostat (LBH589) induces autophagy and apoptosis. Panobinostat effectively disrupts HIV latency in vivo. Phase 3.
Vorinostat (SAHA)

Vorinostat (suberoylanilide hydroxamic acid, SAHA, MK0683, Zolinza) is an HDAC inhibitor with IC50 of ~10 nM in a cell-free assay. Vorinostat abrogates productive HPV-18 DNA amplification.
Entinostat (MS-275)

Entinostat (MS-275, SNDX-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Entinostat induces autophagy and apoptosis. Phase 3.
Trichostatin A (TSA)

Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.
Romidepsin

Romidepsin (FK228, Depsipeptide, FR 901228, NSC 630176) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively. Romidepsin (FK228/depsipeptide) controls growth and induces apoptosis in neuroblastoma tumor cells.
Tubastatin A

Tubastatin A is a potent and selective HDAC6 inhibitor with IC50 of 15 nM in a cell-free assay. It is selective against all the other isozymes (1000-fold) except HDAC8 (57-fold). Tubastatin A promotes autophagy and increases apoptosis.
Mocetinostat (MGCD0103)

Mocetinostat (MGCD0103, MG0103) is a potent HDAC inhibitor with most potency for HDAC1 with IC50 of 0.15 μM in a cell-free assay, 2- to 10- fold selectivity against HDAC2, 3, and 11, and no activity to HDAC4, 5, 6, 7, and 8. Mocetinostat (MGCD0103) induces apoptosis and autophagy. Phase 2.

Download Inhibitor Catalog

HDAC Signaling Pathway Map

Biological Activity

Description

Features

Lead compound of Topotarget.

Targets

HDAC ^[1]
(Cell-free assay)

27 nM

In vitro

Belinostat inhibits the growth of tumor cells (A2780, HCT116, HT29, WIL, CALU-3, MCF7, PC3 and HS852) with IC50 from 0.2-0.66 μM. PD101 shows low activity in A2780/cp70 and 2780AD cells, which are cisplatin and doxorubicin-resistant derivatives of A2780 cells. Belinostat could induce apoptosis through PARP cleavage and acetylation of histones H3/H4. ^[1] Belinostat inhibits bladder cancer cell growth, especially in 5637 cells, which shows accumulation of G0-G1 phase, decrease in S phase and increase in G2-M phase. ^[2] The growth inhibitory activity of belinostat on cell lines is not strongly influenced by the multidrug-resistant phenotype, whereas the activity of docetaxel is clearly affected. Belinostat could enhance the growth inhibitory activity of docetaxel or carboplatin in OVCAR-3 and A2780 cells. Belinostat also shows enhanced tubulin acetylation in ovarian cancer cell lines. ^[3] A recent study shows that Belinostat activates protein kinase A in a TGF-β signaling-dependent mechanism and decreases survivin mRNA. ^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

HCT116	NWf5fFh3TnWwY4Tpc44hSXO\|YYm=	M3PuS\|AvQcLizszNxsA>	M{nRVlI1KGh?		M{nrWoRwf25vcnXneYxifHNiVGOgdJJwfGWrbjDs[ZZmdHNiYX\0[ZIhPsLiaDDpcoN2[mG2aX;u	M1vZWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5MUK0OVk1Lz5zN{GyOFU6PDxxYU6=
HCT116	NHXuW\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MV[0PEBp		NVi1ZpJCTUN3ME2wMlI5KM7:TR?=	NIf6UXo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{GyOFU6PCd-MUexNlQ2QTR:L3G+
Granta-519	M3\C[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MmLkNlQhcA>?		NYnMXY5KUUN3ME21Ok4{KM7:TR?=	Mn7hQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjByNkiwPFAoRjJyME[4NFgxRC:jPh?=
Jeko-1	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NXjXS3FVOjRiaB?=		NYXFXmhTUUN3ME2wMlIh\|ryP	M{PlRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyME[4NFgxLz5{MEC2PFA5ODxxYU6=
HBL-2	MlPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NFrqSVEzPCCq		NHjjSplKSzVyPUCuOEDPxE1?	NHy2Tmw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEC2PFA5OCd-MkCwOlgxQDB:L3G+
Panc-1	MVnBdI9xfG:\|aYOgRZN{[Xl?	M2K4e\|ExOC93MECvNVAxOCCwTR?=	M1zkSlQ5KGh?		M3nDXIlv\HWlZYOg[I9{\SCmZYDlcoRmdnRiYYDvdJRwe2m\|	NYnX[GR[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK2PFE3QThpPkKyOlgyPjl6PD;hQi=>
AsPC-1	MWPBdI9xfG:\|aYOgRZN{[Xl?	NVrkZ2ZQOTByL{WwNE8yODByIH7N	Mn3FOFghcA>?		NHvZRnRqdmS3Y3XzJIRwe2ViZHXw[Y5l\W62IHHwc5B1d3Orcx?=	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjZ6MU[5PEc,OjJ4OEG2PVg9N2F-
T3M4	M1nrT2Fxd3C2b4Ppd{BCe3OjeR?=	M3nqUlExOC93MECvNVAxOCCwTR?=	NGfRcmM1QCCq		MmjubY5lfWOnczDkc5NmKGSncHXu[IVvfCCjcH;weI9{cXN?	M{fGZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NkixOlk5Lz5{Mk[4NVY6QDxxYU6=
Panc-1	MmPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWKwMVgxOCCwTR?=	NEK4WXc1QCCq		MUXpcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36gbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK=	M4m1clxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NkixOlk5Lz5{Mk[4NVY6QDxxYU6=
AsPC-1	MlXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGnlSmMxNThyMDDuUS=>	NF:wPIM1QCCq		M4fofolvcGmkaYTzJINmdGxicILvcIln\XKjdHnvckBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=>	M33xXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NkixOlk5Lz5{Mk[4NVY6QDxxYU6=
T3M4	M33kN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX[wMVgxOCCwTR?=	M3rSeFQ5KGh?		NGL2NnhqdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44hcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI>	MmLJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ4OEG2PVgoRjJ{NkixOlk5RC:jPh?=
MiaPaCa2	NFK2clRHfW6ldHnvckBCe3OjeR?=	NUDIXGJJOS9zMDFOwG0>	MnfjNlQhcA>?		NWftcY42cW6mdXPld{Ah\3Kxd4ToJIFzemW\|dHXkJIlvKEd{L12=	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzR5NU[5OUc,OjN2N{W2PVU9N2F-
AsPc1	MXrGeY5kfGmxbjDBd5NigQ>?	NFzTR\|cyNzFyIN88US=>	NWLq[Y85OjRiaB?=		M2nqNYlv\HWlZYOgJIdzd3e2aDDhdpJme3SnZDDpckBIOi:P	NIDnSJA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{S3OVY6PSd-MkO0O\|U3QTV:L3G+
Panc0403	NU\PWGFJSXCxcITvd4l{KEG\|c3H5	NWDNc2FROSEQvF2=	NETpNlIzPCCq		NFfQWIFqdmS3Y3XzJIFxd3C2b4Ppdy=>	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzR5NU[5OUc,OjN2N{W2PVU9N2F-
Panc1005	M2PaU2Fxd3C2b4Ppd{BCe3OjeR?=	NXT2clNQOSEQvF2=	M{nmfVI1KGh?		NWLXOpNycW6mdXPld{BieG:ydH;zbZM>	MkDWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2N{W2PVUoRjJ\|NEe1Olk2RC:jPh?=
Panc0327	NI\qTG5CeG:ydH;zbZMhSXO\|YYm=	MkDlNUDPxE1?	NIntS3gzPCCq		MXfpcoR2[2W\|IHHwc5B1d3Orcx?=	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzR5NU[5OUc,OjN2N{W2PVU9N2F-
Panc0203	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MY[0PEBp		MkDqSWM2OD1{Mj6yJO69VQ>?	MnPuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2N{W2PVUoRjJ\|NEe1Olk2RC:jPh?=
PL45	MlzGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MWi0PEBp		MYrFR\|UxRTJyLkig{txO	MmfHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2N{W2PVUoRjJ\|NEe1Olk2RC:jPh?=
Panc1005	MnTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MVO0PEBp		MUjFR\|UxRTFwMTFOwG0>	MnL2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2N{W2PVUoRjJ\|NEe1Olk2RC:jPh?=
Panc0403	NXfCb4RtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NGDXNIE1QCCq		MUXFR\|UxRTFwMTFOwG0>	NGLwTWU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{S3OVY6PSd-MkO0O\|U3QTV:L3G+
BxPc3	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NYO0fHV6PDhiaB?=		M{PKXmVEPTB;MT6wJO69VQ>?	M2\QblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NEe1Olk2Lz5{M{S3OVY6PTxxYU6=
MiaPaCa2	M1zxNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MmjLOFghcA>?		NV7ySoprTUN3ME2wMlch\|ryP	M4rwPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NEe1Olk2Lz5{M{S3OVY6PTxxYU6=
Panc0327	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MnfzOFghcA>?		M{K5O2VEPTB;MD61JO69VQ>?	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzR5NU[5OUc,OjN2N{W2PVU9N2F-
AsPc1	NYXtPVBMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NWDmXWFSPDhiaB?=		MXzFR\|UxRTBwMzFOwG0>	NGPMOlg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{S3OVY6PSd-MkO0O\|U3QTV:L3G+
PC9	MVHGeY5kfGmxbjDBd5NigQ>?	Mme3NE42NzFxMjFOwG0>	MoXrOEBp	NWDiW4tJTE2VTx?=	NFH2NJdqdmirYnn0d{B1cGVibHX2[Yx{KG:oIFHreEApeC2Da4SpJIFv\CCHR1\S	NUjjbmhyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1NVU4PTJpPkKzOVE2PzV{PD;hQi=>
H1650	NIiwW3RHfW6ldHnvckBCe3OjeR?=	NWHFW5VwOC53L{GvNkDPxE1?	NH;zRoc1KGh?	NYPicld3TE2VTx?=	M{XhSIlvcGmkaYTzJJRp\SCuZY\lcJMhd2ZiQXv0JEhxNUGtdDmgZY5lKEWJRmK=	NVrTN401RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1NVU4PTJpPkKzOVE2PzV{PD;hQi=>
H460	M{[0RWZ2dmO2aX;uJGF{e2G7	M4C5fVAvPS9zL{Kg{txO	M1XH[\|QhcA>?	Mme0SG1UVw>?	NVKzfZI4cW6qaXLpeJMhfGinIHzleoVteyCxZjDBb5QhMHBvQXv0LUBidmRiRVfGVi=>	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzVzNUe1Nkc,OjN3MUW3OVI9N2F-
PC9	NXKySVRLTnWwY4Tpc44hSXO\|YYm=	NXPzNmtiPTBywrDuUS=>	MU[yOOKhcA>?	NEjpSpBFVVOR	M4nLNoRm[3KnYYPld{BGT0[UIHX4dJJme3Orb36=	NXe5Um51RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1NVU4PTJpPkKzOVE2PzV{PD;hQi=>
H1650	NFvwenNHfW6ldHnvckBCe3OjeR?=	M4rh[lUxOMLibl2=	NWPmZ3BNOjUEoHi=	MXLEUXNQ	M2PtS4Rm[3KnYYPld{BGT0[UIHX4dJJme3Orb36=	NHHu[HY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{WxOVc2Oid-MkO1NVU4PTJ:L3G+
H460	MYnGeY5kfGmxbjDBd5NigQ>?	MVy1NFDDqG6P	MlXvNlTDqGh?	M3;aOGROW09?	M4L5XYRm[3KnYYPld{BGT0[UIHX4dJJme3Orb36=	NWHTeWtkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1NVU4PTJpPkKzOVE2PzV{PD;hQi=>
HCC4006	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MX[3NuKhcA>?	MX;EUXNQ	NV7mZXJFUUN3ME2wMlQ3KM7:TR?=	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzVzNUe1Nkc,OjN3MUW3OVI9N2F-
HCC2935	M4TRSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M3ztZlczyqCq	MWPEUXNQ	NVPDfHVFUUN3ME2wMlk4KM7:TR?=	MnfTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3MUW3OVIoRjJ\|NUG1O\|UzRC:jPh?=
HCC827	M3;QVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NVzzZ49LPzMEoHi=	NVmyRZNjTE2VTx?=	NYGyOmpoUUN3ME2wMlI6KM7:TR?=	MnXWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3MUW3OVIoRjJ\|NUG1O\|UzRC:jPh?=
HCC2279	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MXu3NuKhcA>?	NWfnVZd6TE2VTx?=	NE[xOppKSzVyPUCuOEDPxE1?	NW\NXZo{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1NVU4PTJpPkKzOVE2PzV{PD;hQi=>
PC9	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NFPURZY4OsLiaB?=	M{SwdGROW09?	MnfwTWM2OD1yLkK5JO69VQ>?	M4TWbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NUG1O\|UzLz5{M{WxOVc2OjxxYU6=
H820	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MnKwO\|LDqGh?	MkHPSG1UVw>?	MYXJR\|UxRTBwNDFOwG0>	NWjOfJNRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1NVU4PTJpPkKzOVE2PzV{PD;hQi=>
H1650	MmG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NWnqVI5CPzMEoHi=	MX7EUXNQ	MoX2TWM2OD1yLki4JO69VQ>?	MoHOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3MUW3OVIoRjJ\|NUG1O\|UzRC:jPh?=
H1975	NY\CZmtnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NV7EVIVUPzMEoHi=	M1HTOGROW09?	NVvLWW5[UUN3ME2wMlY5KM7:TR?=	NXjkNGVrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1NVU4PTJpPkKzOVE2PzV{PD;hQi=>
H520	MlXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NV63VpNoPzMEoHi=	NILKeJdFVVOR	NG\4RXRKSzVyPUCuO\|Uh\|ryP	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzVzNUe1Nkc,OjN3MUW3OVI9N2F-
H1299	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MoL6O\|LDqGh?	MnLiSG1UVw>?	MljHTWM2OD1zLkKg{txO	Ml\zQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3MUW3OVIoRjJ\|NUG1O\|UzRC:jPh?=
H460	NFG2OVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MXe3NuKhcA>?	MoTqSG1UVw>?	MlvrTWM2OD1yLki2JO69VQ>?	M2jBVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NUG1O\|UzLz5{M{WxOVc2OjxxYU6=
H1666	MnHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		Mm\uO\|LDqGh?	NG\IZWdFVVOR	MWTJR\|UxRjFyIN88US=>	M1n2PFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NUG1O\|UzLz5{M{WxOVc2OjxxYU6=
PANC-1	M{\JPWZ2dmO2aX;uJGF{e2G7	NYLEUINxOTEEoN88US=>	NInoNIMzNzRiaB?=	MluwSG1UVw>?	NGLS[lhqdmO{ZXHz[ZMhcW62cnHj[YxtfWyjcjDSU3MhdGW4ZXy=	NGDvSlc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{e0N\|E6QCd-MkO3OFMyQTh:L3G+
PANC-1	NVnzdYhrS2WubDDWbYFjcWyrdImgRZN{[Xl?	NV61WHVsOS9zMNMg{txO	NETXWpo1QCCq	NXLRb\|d[TE2VTx?=	MWTk[YNz\WG\|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ?	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd2M{G5PEc,OjN5NEOxPVg9N2F-
PANC-1	NUPRcHVLTnWwY4Tpc44hSXO\|YYm=	MVuxNOKh\|ryP	M1nlZVIwPC94IHi=	MnXJSG1UVw>?	MoX5bY5lfWOnczDBUXBMKGGldHn2ZZRqd25?	MlGxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5NEOxPVgoRjJ\|N{SzNVk5RC:jPh?=
HL-60	MXnGeY5kfGmxbjDBd5NigQ>?	MoDKNE4zyqEQvF2=	M{\iWFI1NzR6L{eyJIg>		MYnlcohidmOnczDSRU1qdmS3Y3XkJIdz[W63bH;jfZRq[yCmaX\m[ZJmdnSrYYTpc44>	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh4NEezNkc,OjV6NkS3N\|I9N2F-
NB4	NEeyOGlHfW6ldHnvckBCe3OjeR?=	MnzPNE4zyqEQvF2=	NX:4TJB{OjRxNEivO\|IhcA>?		NGrXXIZmdmijbnPld{BTSS2rbnT1Z4VlKGe{YX71cI9kgXSrYzDkbYZn\XKnboTpZZRqd25?	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh4NEezNkc,OjV6NkS3N\|I9N2F-
HL-60	NGDoSVVHfW6ldHnvckBCe3OjeR?=	NFjGNGUzyqEQvF2=	NH\Tc\|IzPC92ODDo		NGPSfGNjdG:la4OgZ4VtdCCleXPs[UBqdiCVIIDoZZNm	NHT1OnQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUi2OFc{Oid-MkW4OlQ4OzJ:L3G+
NB4	NWXydGs2TnWwY4Tpc44hSXO\|YYm=	MVKyxsDPxE1?	M3viPVI1NzR6IHi=		MkD6Zoxw[2u\|IHPlcIwh[3mlbHWgbY4hWyCyaHHz[S=>	NVSyVo5yRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4OlQ4OzJpPkK1PFY1PzN{PD;hQi=>
HL-60	MXvD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	M3X4NVAvOi9{wrFOwG0>	MX:yOE81QC95MjDo		MX\k[YNz\WG\|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZo91cCC2aX3lJIFv\CCmb4PlJIRmeGWwZHXueEBu[W6wZYK=	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh4NEezNkc,OjV6NkS3N\|I9N2F-
NB4	MUfD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	NGPndlgxNjJxMtMg{txO	Moi2NlQwPDhxN{KgbC=>		NIjpTGFl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[m:2aDD0bY1mKGGwZDDkc5NmKGSncHXu[IVvfCCvYX7u[ZI>	NHnHRnQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUi2OFc{Oid-MkW4OlQ4OzJ:L3G+
RAW264.7	MYTBcpRqNWmwZnzhcY1ifG:{eTDhd5NigQ>?		Mk\6NUBpeg>?		NHnLUYVCdnSrLXnu[oxidW2jdH;yfUBi[3Srdnn0fUBqdiCOUGOtd5RqdXWuYYTl[EBud3W\|ZTDSRXczPjRwNzDj[YxteyCjc4Pld5Nm\CCjczDzeZBxemW\|c3nvckBw\iCLTE[gdJJw\HWldHnvckBxemVvaX7jeYJifGWmIH\vdkAyKGi{IHLl[o9z\SCOUGOgd5RqdXWuYYTpc44h\m:{IEK0JIhzeyCkeTDFUGlUSSCvZYToc4QtKEmFNUCgQUAxNjByMEC1PUDPxE1w	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTFzM{i3OUc,OjVzMUO4O\|U9N2F-
HEK293	Ml:zSpVv[3Srb36gZZN{[Xl?				M2PCUGlvcGmkaYTpc44hd2ZiSFTBR\|YhcW5iSFXLNlk{KGOnbHzzMEBKSzVyIE2gNE4xOTVizszNMi=>	NWi1UnZWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUizNFg2PjNpPkG4N\|A5PTZ\|PD;hQi=>
HEK293	MlzvSpVv[3Srb36gZZN{[Xl?				NFu3VFJKdmirYnn0bY9vKG:oIFjERWMyKGmwIFjFT\|I6OyClZXzsd{whUUN3MDC9JFAvODF6IN88UU4>	NFLlepY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEOwPFU3Oyd-MUizNFg2PjN:L3G+
HeLa	M{DvXGZ2dmO2aX;uJIF{e2G7		MXSzNEBucW6\|		Mnn1TY5pcWKrdHnvckBw\iCKRFHDJIlvKGi3bXHuJGhmVGFiY3XscJMhdnWlbHXhdkBmgHS{YXP0d{BqdmO3YnH0[YQh\m:{IEOwJI1qdnNiYomg[ox2d3Knc3PlcpQh[XO\|YYmsJGlEPTBiPTCwMlAzPjRizszNMi=>	NF\GSYk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUGxN\|g4PSd-MkWxNVM5PzV:L3G+
HeLa	NITp[\|VHfW6ldHnvckBie3OjeR?=				MoXBTY5pcWKrdHnvckBw\iCKRFHDJIlvKGi3bXHuJGhmVGFiY3XscJMhfXOrbnegSox2d3JiZHWgUJl{KGG\|IIP1ZpN1emG2ZTDifUBndHWxcnXzZ4Vv[2ViYYPzZZktKEmFNUCgQUAxNjB{NzFOwG0v	M4nEWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NkO5OVM4Lz5{M{[zPVU{PzxxYU6=
HeLa	M4fEe2Z2dmO2aX;uJIF{e2G7				NWrFfmtoUW6qaXLpeIlwdiCxZjDISGFEKG[{b32gbJVu[W5iSHXMZUBk\WyuczygTWM2OCB;IECuNFI5KM7:TT6=	M1LMTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6MkS3OVU1Lz5zOEK0O\|U2PDxxYU6=
HEK293	M4fqZ2Z2dmO2aX;uJIF{e2G7				MXLJcohq[mm2aX;uJI9nKEiGQVOzJIlvKEiHS{K5N{Bk\WyuczygTWM2OCB;IECuNFQ3KM7:TT6=	NGHyS449[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEOwPFU3Oyd-MUizNFg2PjN:L3G+
MDA-MB-231	NXv3UFR5SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MV23NkBpenN?		NHTQSmpCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3ERU1OSi1{M{GgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KHKnc3H6eZJqdiCmeXWgZoF{\WRiZnz1c5Jme2OnbnPlJIF{e2G7LDDJR\|UxKD1iMD6wOlIh\|ryPLh?=	NFnIWW89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUS1OlgxPCd-Mkm0OVY5ODR:L3G+
Jurkat	M4LNeGFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NVvsO3VRPDhiaILz		M1TtW2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSoXyb4F1KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCwMlA4KM7:TT6=	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTV\|M{i3N{c,Ojl3M{O4O\|M9N2F-
A549	NVfCeGhWSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MonaO\|IhcHK\|		NVTRTZI{SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDy[ZNignW{aX6g[JlmKGKjc3XkJIZtfW:{ZYPj[Y5k\SCjc4PhfUwhUUN3MDC9JFAvODd5IN88UU4>	M{LHNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEW2PFA1Lz5{OUS1OlgxPDxxYU6=
HeLa	NXHxNok1SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NHH2R\|I4OiCqcoO=		NGTkSIpCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjlUIEh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IILld4F7fXKrbjDkfYUh[mG\|ZXSg[ox2d3Knc3PlcoNmKGG\|c3H5MEBKSzVyIE2gNE4xQDdizszNMi=>	MnvjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2NU[4NFQoRjJ7NEW2PFA1RC:jPh?=
MCF7	NVrIPZVISW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NUXMcGZrPzJiaILz		MWjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2FRkegZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KHKnc3H6eZJqdiCmeXWgZoF{\WRiZnz1c5Jme2OnbnPlJIF{e2G7LDDJR\|UxKD1iMD6wPVYh\|ryPLh?=	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR3NkiwOEc,Ojl2NU[4NFQ9N2F-
HEL	M4HDfmFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NGTCfHQ1QCCqcoO=		NEDUbVVCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjFUEBk\WyuczDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMD6xJO69VS5?	NX24VZZDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm1N\|M5PzNpPkK5OVM{QDd\|PD;hQi=>
Huh7	MYnBcpRqfmm{YXygZZN{[Xl?		NEezNGg{KGSjeYO=		NWrVXlJ3SW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUEOYIHflco91gXCnIEHiJIlv\mWldHXkJIlvKGi3bXHuJGh2cDdiY3XscJMh[W[2ZYKgN{Bl[Xm\|IHL5JIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigSxiRVO1NEA:KDBwMUKg{txONg>?	NHHiS3c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUS5NFcxOCd-MkW0PVA4ODB:L3G+
HCT116	MlvSRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NXi4U\|dUPDhiaILz		M3zx[mFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFPUNVE3KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDTVmIh[XO\|YYmsJGdKPTBiPTCwMlE{KM7:TT6=	MmrFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd\|NES0PFcoRjJ5M{S0OFg4RC:jPh?=
MOLT4	M4\lRmFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NGmwemc1QCCqcoO=		MmXDRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPT1zUOEBk\WyuczDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMD6xOEDPxE1w	Mln1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl3M{O4O\|MoRjJ7NUOzPFc{RC:jPh?=
HCT116	MXvBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?				NYTmbWhTSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMh[XO\|ZYPz[YQh[XNiZ4Lve5RpKGmwaHnibZRqd25uIFnDOVAhRSByLkG2JO69VS5?	M{jycVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNkWwNlIyLz5{MU[1NFIzOTxxYU6=
HCT116	MXnBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?				NVGzc2pmSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMtKEmFNUCgQUAxNjF4IN88UU4>	MkHyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5NEK0PVYoRjJzN{SyOFk3RC:jPh?=
SK-N-BE(2)	M1nObmFvfGmycn;sbYZmemG2aY\lJIF{e2G7		M3j4dlQ5KGi{cx?=		NWDmU2pQSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDTT{1PNUKHKEKpJINmdGy\|IHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSByLkOxJO69VS5?	NV\FdVZ{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm1N\|M5PzNpPkK5OVM{QDd\|PD;hQi=>
PC3	MkHRRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NHOzPYQ1QCCqcoO=		NWezbmIySW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDQR\|Mh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IGPSRkBie3OjeTygS2k2OCB;IECuN\|kh\|ryPLh?=	MlLoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd\|NES0PFcoRjJ5M{S0OFg4RC:jPh?=
PC3	MYnBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MV:5OkBpenN?		M1vpcGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iUFOzJINmdGy\|IHHmeIVzKDl4IHjyd{BjgSClZXzseIl1\XJiOU[gZZN{[XluIFnDOVAhRSByLkS1JO69VS5?	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTZ\|NESzNEc,OjF4M{S0N\|A9N2F-
H1299	M3X4[2FvfGmycn;sbYZmemG2aY\lJIF{e2G7				NW\0VmloSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDINVI6QSClZXzsd{whUUN3MDC9JFAvPDZizszNMi=>	NFu0OGE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MU[1NFIzOSd-MkG2OVAzOjF:L3G+
HeLa	MkXERY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NIO3OIc1QCCqcoO=		MYPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEinTHGgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDBwNUGg{txONg>?	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTV\|M{i3N{c,Ojl3M{O4O\|M9N2F-
HCT116	MoP2RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NIXV[Vc6PiCqcoO=		NFXUSWhCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjDWFEyPiClZXzsd{Bi\nSncjC5OkBpenNiYomgZ4VtdHSrdHXyJFk3KGG\|c3H5MEBKSzVyIE2gNE43KM7:TT6=	M1TzfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNkO0OFMxLz5{MU[zOFQ{ODxxYU6=
A2780	M2TicGFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MX:5OkBpenN?		NYPOUoZLSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBNlc5OCClZXzsd{Bi\nSncjC5OkBpenNiYomgZ4VtdHSrdHXyJFk3KGG\|c3H5MEBKSzVyIE2gNE43PyEQvF2u	NFWwbnE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MU[zOFQ{OCd-MkG2N\|Q1OzB:L3G+
HuH7	M1TIS2N6fG:2b4jpZ4l1gSCjc4PhfS=>		MWKzJIRigXN?		NH7rNXJEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJfUh5IHPlcIx{KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4Yh[2WubDD2bYFjcWyrdImgZYZ1\XJiMzDkZZl{KGK7IFPlcIxVcXSncjC5OkBie3OjeTygR2M2OCB;IECuOlgh\|ryPLh?=	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR7MEewNEc,OjV2OUC3NFA9N2F-
COLO205	M2\nTGFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NWjrT2FrQTZiaILz		M1fwfGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQ1;MU\|IxPSClZXzsd{Bi\nSncjC5OkBpenNiYomgZ4VtdHSrdHXyJFk3KGG\|c3H5MEBKSzVyIE2gNE44KM7:TT6=	M1;welxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNkO0OFMxLz5{MU[zOFQ{ODxxYU6=
A549	NFX0OIFCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		M3jiOFQ5KGi{cx?=		MlexRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCDNUS5JINmdGy\|IHHmeIVzKDR6IHjyd{BjgSCVUlKgZZN{[XluIFfJOVAhRSByLke4JO69VS5?	M2LHNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5M{S0OFg4Lz5{N{O0OFQ5PzxxYU6=
HL60	MlHDRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		Mnj1OFghcHK\|		NWnWUWlYSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIUFYxKGOnbHzzJIFnfGW{IES4JIhzeyCkeTDTVmIh[XO\|YYmsJGdKPTBiPTCxMlA6KM7:TT6=	NEOwfZM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{O0OFQ5Pyd-MkezOFQ1QDd:L3G+
K562	M3i4S2FvfGmycn;sbYZmemG2aY\lJIF{e2G7		MkfjOFghcHK\|		NYntRoRnSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDLOVYzKGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCxMlEh\|ryPLh?=	NFHSXYo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUWzN\|g4Oyd-Mkm1N\|M5PzN:L3G+
PC3	M4LmfmFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NGD4XmU1QCCqcoO=		M2PEUWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iUFOzJINmdGy\|IHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSBzLkOg{txONg>?	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTV\|M{i3N{c,Ojl3M{O4O\|M9N2F-
NFF	M3LXSGN6fG:2b4jpZ4l1gSCjc4PhfS=>		MofBO\|IhcHK\|		MYPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDOSmYh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IGPSRkBie3OjeTygTWM2OCB;IEGuOEDPxE1w	M1nX[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkSxNVEzLz5{OEK0NVEyOjxxYU6=
HEK293	NEPL[GtEgXSxdH;4bYNqfHliYYPzZZk>		MV20PEBpenN?		M3TD[mN6fG:2b4jpZ4l1gSCjZ3HpcpN1KEiHS{K5N{Bk\WyuczDh[pRmeiB2ODDodpMh[nlicnXzZZp2emmwIHHzd4F6NCCLQ{WwJF0hOS52IN88UU4>	NWfDOW1LRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyOFEyOTJpPkK4NlQyOTF{PD;hQi=>
NFF	MofnR5l1d3SxeHnjbZR6KGG\|c3H5		NUPacoVIPzJiaILz		M2PzNWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG5HTiClZXzsd{Bi\nSncjC3NkBpenNiYomgd5Vt\m:{aH;kZY1qdmViQjDhd5NigSxiSVO1NEA:KDFwNEKg{txONg>?	Mn3HQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB{NEW0NFIoRjNyMkS1OFAzRC:jPh?=
HEK293	NVrucGRYS3m2b4TvfIlkcXS7IHHzd4F6		NHXTXoQ1QCCqcoO=		NWHqbXZCS3m2b4TvfIlkcXS7IHHnZYlve3RiSFXLNlk{KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDy[ZNignW{aX6g[JlmKGKjc3XkJIF{e2G7LDDJR\|UxKD1iMT60NkDPxE1w	NUW0XWhXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CyOFU1ODJpPkOwNlQ2PDB{PD;hQi=>
RAW264.7	NUHydlRISW62aT3pcoZt[W2vYYTvdpkh[XO\|YYm=		NH3SXmsyKGi{		NXm3d2tFSW62aT3pcoZt[W2vYYTvdpkh[WO2aY\peJkhcW5iTGDTMZN1cW23bHH0[YQhdW:3c3WgVmFYOjZ2LkegZ4VtdHNiYYPz[ZN{\WRiYYOgd5VxeHKnc4Ppc44hd2Zibnn0dolkKG:6aXTlJJBzd2S3Y4Tpc44heHKnLXnuZ5Vj[XSnZDDmc5IhOSCqcjDi[YZwemViTGDTJJN1cW23bHH0bY9vKG[xcjCyOEBpenNiYomgS5Jq\XO\|IILlZYdmdnRiYnHz[YQh[XO\|YYmsJGlEPTBiPTCyMlIh\|ryPLh?=	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTFzM{i3OUc,OjVzMUO4O\|U9N2F-
RAW264.7	M3XVU2FvfGlvaX7mcIFudWG2b4L5JIF{e2G7		NVLpS3JsOSCqch?=		NHzCW5FCdnSrLXnu[oxidW2jdH;yfUBi[3Srdnn0fUBqdiCOUGOtd5RqdXWuYYTl[EBud3W\|ZTDSRXczPjRwNzDj[YxteyCjc4Pld5Nm\CCjczDzeZBxemW\|c3nvckBw\iCWTl\hcJBp[SCycn;keYN1cW:wIIDy[U1qdmO3YnH0[YQh\m:{IEGgbJIh[mWob4LlJGxRWyC\|dHnteYxifGmxbjDmc5IhOjRiaILzJIJ6KEWOSWPBJI1mfGixZDygTWM2OCB;IESuO{DPxE1w	NGTUdXA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUGxN\|g4PSd-MkWxNVM5PzV:L3G+
RAW264.7	NULaNZFWSW62aT3pcoZt[W2vYYTvdpkh[XO\|YYm=		Mlz3NUBpeg>?		M2PZdmFvfGlvaX7mcIFudWG2b4L5JIFkfGm4aYT5JIlvKEySUz3zeIlufWyjdHXkJI1wfXOnIGLBW\|I3PC55IHPlcIx{KGG\|c3Xzd4VlKGG\|IIP1dJBz\XO\|aX;uJI9nKFCJRUKgdJJw\HWldHnvckBxemVvaX7jeYJifGWmIH\vdkAyKGi{IHLl[o9z\SCOUGOgd5RqdXWuYYTpc44h\m:{IEK0JIhzeyCkeTDlcpp6dWViaX3teY5w[XO\|YYmgcYV1cG:mLDDJR\|UxKD1iOD6yPEDPxE1w	Mn3TQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzMUO4O\|UoRjJ3MUGzPFc2RC:jPh?=
Huh-luc/neo7	M3L0emZ2dmO2aX;uJIF{e2G7	M{L2clEhfU1?	NYT0UFNDOSC2bzCzJIhzew>?		M1voemlvcGmkaYTpc44hd2ZiSFTBR{BkdGG\|czCxJIlvKGi3bXHuJGh2cC2udXOvcoVwPyClZXzsd{Bie3Onc4Pl[EBieyCqaYP0c45mKEh\|IHHj[ZR6dGG2aX;uJIF1KDFidV2gZYZ1\XJiMTD0c{A{KGi{czDifUBY\XO2ZYLuJIJtd3S2aX7nJIFv[Wy7c3nz	NWfVNGZFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5N\|cxOTdpPkK1PVM4ODF5PD;hQi=>
PC3	M1XqZ2Z2dmO2aX;uJIF{e2G7	MX[wMlMhfU1?	NIjY[lY1QCCqcoO=		MX3Jcohq[mm2aX;uJI9nKEiGQVOgbY4hcHWvYX6gVGM{KGOnbHzzJIF{e2W\|c3XkJIF{KGmwY4LlZZNmKGmwIHHtc5VvfCCxZjDhZ4V1gWyjdHXkJIhqe3SxbnWgTFMh[XRiMD6zJJVOKGGodHXyJFQ5KGi{czDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXN?	NV32fmhvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkezOFQ1QDdpPkK3N\|Q1PDh5PD;hQi=>
HCT116	MUfGeY5kfGmxbjDhd5NigQ>?	M1zDZlAvOyC3TR?=	MX:0PEBpenN?		Mkf0TY5pcWKrdHnvckBw\iCKRFHDJIlvKGi3bXHuJGhEXDFzNjDj[YxteyCjc4Pld5Nm\CCjczDpcoNz\WG\|ZTDpckBidW:3boSgc4Yh[WOndInsZZRm\CCqaYP0c45mKEh\|IHH0JFAvOyC3TTDh[pRmeiB2ODDodpMh[nliV3XzeIVzdiCkbH;0JIFv[Wy7c3nz	NXLlWGdkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkezOFQ1QDdpPkK3N\|Q1PDh5PD;hQi=>

Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID

Western blot	p-H2AX(Ser139) / KU70 / KU80 / RAD51 / RAD52 / ERCC1 ; Acetyl Histone H3 / Acetyl Histone H4 / Acetyl tubulin ; p21 / p27 ; SOS1 / SOS2 ; PARP / p-ERK / p-p38 / p38 / p-BRAF / p-MEK / MEK	24155971 23982416 28397399
Growth inhibition assay	Cell viability ; IC50	24155971 28397399

In vivo

Belinostat indicates significant tumor growth delay in A2780 and A2780/cp70 xenograft at a dose of 10mg/kg with no effects on the body weight. ^[1] Belinostat also induces p21WAF1, HDAC core and cell communication genes in mouse bladder tumors. ^[2] Belinostat monotherapy induces dose-proportional antitumor effects with TGI of 47% at a dose of 100mg/kg in A2780 xenograft. The combination of Belinostat (100 mg/kg) with carboplatin (40 mg/kg) could delay tumor growth from 18.6 days to 22.5 days. ^[3] Combining with bortezomib, Belinostat results in great tumor inhibition and gastrointestinal toxicity in mice with bortezomib-resistant UMSCC-11A xenograft. ^[5]

Protocol (from reference)

Kinase Assay:^[1]	Histone Deacetylase Activity: Subconfluent cultures are harvested and washed twice in ice cold PBS and pelleted by centrifugation at 200 × g for 5 min. The cell pellet is resuspended in two volumes of lysis buffer [60 mM Tris buffer (pH 7.4) containing 30% glycerol and 450 mM NaCl] and lysed by three freeze (dry ice) thaw (30 °C water bath) cycles. Cell debris is removed by centrifugation at 1.2 × 10⁴ g for 5 min, and the supernatant is stored at −80 °C. Histone H4 peptide (sequence SGRGKGGKGLGKGGAKRHRK corresponding to the 20 NH2-terminal residues) is acetylated by a recombinant protein containing the hypoxanthine-aminopterin-thymidine domain of p300, using [³H]acetyl CoA as a source of acetate. H4 peptide (100 μg) is mixed with hypoxanthine-aminopterin-thymidine buffer (50 mM Tris HCl pH 8.0, 5% glycerol, 50 mM KCl, and 0.1 mM EDTA), 1 mM DTT, 1 mM 4-(2-aminoethyl) benzenesulfonylfluoride, 1 × complete protease inhibitors, 50 μL of purified p300, and 1.85 m [³H]acetyl CoA (4.50Ci/mmol) in a final volume of 300 μL and incubated at 30 °C for 45 min. The p300 protein is removed by incubation with 20 μL of 50% Ni-agaroase beads for 1 hour at 4 °C and centrifugation. The supernatant is applied to a 2 mL Sephadex G15 column, and the flow through is collected. One milliliter of distilled H₂O is gently applied, and three drop fractions are collected; this is repeated until 4–5 mL of distilled H₂O has been added, and ∼40 fractions are collected. Three microliters of each fraction are diluted in 2 mL of scintillation fluid and counted in a scintillation counter to identify the fractions containing the labeled peptide. These fractions are pooled, and 1 μL of the combined sample is measured to assess the radioactivity in every peptide batch (3-7×10³ cpm/μL). For activity assays, the reaction is carried out in a total volume of 150 μL of buffer [60 mM Tris (pH 7.4) containing 30% glycerol] containing 2 μL of cell extract and, where used, 2 μL of belinostat. The reaction is started by the addition of 2 μL of [³H] labeled substrate (acetylated histone H4 peptide corresponding to the 20 NH₂-terminal residues). Samples are incubated at 37 °C for 45 min, and the reaction stopped by the addition of HCl and acetic acid (0.72 and 0.12 M final concentrations, respectively). Released [³H]acetate is extracted into 750 μL of ethyl acetate, and samples are centrifuged at 1.2× 10⁴ g for 5 min. The upper phase (600 μL) is transferred to 3 mL of scintillation fluid and counted.
Cell Research:^[1]	Cell lines: A2780, A2780/cp70, 2780AD, HCT116, HT29, WIL, CALU-3, MCF7, PC3 and HS852 Concentrations: 0.016 - 10 μM Incubation Time: 24 hours Method: Tumor cell lines are seeded in 5 mL of medium at a density of 8 × 10⁴ cells/25 cm2 flask and incubated for 48 hours. Cells are exposed to Belinostat (0.016 to 10 μM) for 24 hours. The medium is removed, and 1 mL of trypsin/EDTA is added to each flask. Once the cells have detached, 1 mL of medium is added, the cells are resuspended, and those from the control untreated flask are counted. Cells are diluted and plated into 6-cm Petri dishes (three per flask) at a density of 0.5-2× 10³ cells/dish depending on the cell line. Cells from the drug-treated flasks are diluted and plated as for the control flasks. Dishes are incubated for 10–15 days at 37 °C. Cells are washed with PBS, fixed in methanol, and stained with crystal violet, and colonies that contained ≥50 cells counted. Sensitivity is expressed as the IC50 defined as the concentration of belinostat required to reduce the number of colonies to 50% of that of the control untreated cells.
Animal Research:^[1]	Animal Models: A2780, A2780/cp70 and HCT116 cells are injected s.c. into the right flank of CD1 nu/nu mice. Dosages: ≤40 mg/kg Administration: Administered via i.p.

References

+ Expand

Solubility (25°C)

In vitro


In vivo	Add solvents to the product individually and in order (Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+ddH2O For best results, use promptly after mixing. Click to purchase: PEG300	10mg/mL

Chemical Information

Molecular Weight	318.35
Formula	C₁₅H₁₄N₂O₄S
CAS No.	414864-00-9
Storage	3 years	-20°C	powder
Storage	2 years	-80°C	in solvent
Smiles	C1=CC=C(C=C1)NS(=O)(=O)C2=CC=CC(=C2)C=CC(=O)NO

Download Belinostat (PXD101) SDF

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

Clinical Trial Information

NCT Number	Recruitment	Interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04315233	Recruiting	Drug: Ribociclib\|Drug: Belinostat	Metastatic Breast Cancer\|Recurrent Ovarian Carcinoma	University of Utah\|Novartis\|Acrotech Biopharma	May 3 2021	Phase 1
NCT04703920	Recruiting	Drug: Talazoparib\|Drug: Belinostat	Metastatic Breast Cancer\|Metastatic Castration-resistant Prostate Cancer\|Metastatic Ovarian Carcinoma	University of Michigan Rogel Cancer Center\|Pfizer\|Acrotech Biopharma LLC	March 4 2021	Phase 1
NCT03772925	Recruiting	Drug: Belinostat\|Drug: Pevonedistat	Recurrent Acute Myeloid Leukemia\|Recurrent Myelodysplastic Syndrome\|Refractory Acute Myeloid Leukemia\|Refractory Myelodysplastic Syndrome	National Cancer Institute (NCI)	February 28 2019	Phase 1
NCT02680795	Completed	Drug: Belinostat IV	Solid Tumors\|Hematological Malignancies	Acrotech Biopharma LLC\|Axis Clinicals Limited	April 27 2016	Phase 1
NCT02679131	Terminated	Drug: Belinostat	Relapsed/Refractory Solid Tumors/Hematological Malignancies	Acrotech Biopharma LLC\|Axis Clinicals Limited	March 2016	Phase 1

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Frequently Asked Questions

Question 1:
Could you please give some suggestions for the use of Belinostat in vivo (i.p. injection)?

Answer:
For I.P. injection, S1085 Belinostat (PXD101) can be dissolved in 2% DMSO+30% PEG 300+ddH2O at 10 mg/ml clearly. When preparing the solution, please dissolve the compound in DMSO clearly first. Then add PEG, after they mixed well, then dilute with water. Hope this information is useful to you.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):